Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
117 hedge funds and large institutions have $1.35B invested in Verona Pharma in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 8 closing their positions.
188% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 8
26% more capital invested
Capital invested by funds: $1.07B → $1.35B (+$279M)
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
15% more funds holding
Funds holding: 102 → 117 (+15)
2.39% more ownership
Funds ownership: 82.14% → 84.53% (+2.4%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
55% less call options, than puts
Call options by funds: $2.16M | Put options by funds: $4.82M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$24.5M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$14M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$8.61M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.79M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$6.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.4M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$15.1M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$14.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.1M |
| 5 |
Millennium Management
New York
|
-$8.13M |
VRNA Hedge Fund Activity: Q4 2023 in Review
117 of the 6,872 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2023, worth a combined $1.35B — up 26% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VRNA positions and 8 closed out — a net gain of 15 holders — while 38 added to existing stakes and 32 trimmed.
The largest buyer was Maverick Capital, opening a new position worth an estimated $24.5M. The largest seller was Fidelity Investments, cutting an estimated $30.4M.
- 117 institutional investors held Verona Pharma (VRNA) as of Q4 2023, up from 102 in Q3 2023.
- Funds reported $1.35B of Verona Pharma stock for Q4 2023, up 26% quarter-over-quarter.
- 23 funds opened new Verona Pharma positions in Q4 2023 and 8 closed out, a net change of +15 holders.
- The largest Verona Pharma buyer in Q4 2023 was Maverick Capital, an estimated $24.5M added.
- The largest Verona Pharma seller in Q4 2023 was Fidelity Investments, an estimated $30.4M sold.
Based on aggregated 13F filings for Q4 2023.